Market Closed -
Nasdaq
01:30:00 27/04/2024 am IST
|
5-day change
|
1st Jan Change
|
31.49
USD
|
-0.57%
|
|
+6.64%
|
+41.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,265
|
3,001
|
1,785
|
1,543
|
1,245
|
1,788
|
-
|
-
|
Enterprise Value (EV)
1 |
3,184
|
2,690
|
1,582
|
1,421
|
1,215
|
1,719
|
1,824
|
1,675
|
P/E ratio
|
-6.96
x
|
-9.14
x
|
1.24
x
|
-6.64
x
|
-3.52
x
|
-5.75
x
|
-5.35
x
|
-7.06
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
27.7
x
|
14.8
x
|
-
|
108
x
|
46.4
x
|
42.3
x
|
15.7
x
|
9.05
x
|
EV / Revenue
|
27
x
|
13.2
x
|
-
|
99.8
x
|
45.3
x
|
40.7
x
|
16
x
|
8.48
x
|
EV / EBITDA
|
-7.61
x
|
-8.79
x
|
-4.29
x
|
-3.73
x
|
-3.16
x
|
-5.1
x
|
-4.47
x
|
-4.69
x
|
EV / FCF
|
-8.32
x
|
-8.8
x
|
-3.83
x
|
-4.52
x
|
-4.09
x
|
-5.12
x
|
-7.37
x
|
-7.15
x
|
FCF Yield
|
-12%
|
-11.4%
|
-26.1%
|
-22.1%
|
-24.5%
|
-19.5%
|
-13.6%
|
-14%
|
Price to Book
|
4.47
x
|
7.48
x
|
1.54
x
|
1.4
x
|
1.53
x
|
2.52
x
|
2.75
x
|
3.4
x
|
Nbr of stocks (in thousands)
|
68,371
|
69,260
|
54,308
|
54,945
|
55,891
|
56,773
|
-
|
-
|
Reference price
2 |
47.75
|
43.33
|
32.87
|
28.08
|
22.27
|
31.49
|
31.49
|
31.49
|
Announcement Date
|
13/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
117.9
|
203.2
|
-
|
14.24
|
26.82
|
42.22
|
113.7
|
197.5
|
EBITDA
1 |
-418.2
|
-306.2
|
-369.2
|
-380.5
|
-384.9
|
-337.3
|
-408.3
|
-357
|
EBIT
1 |
-426.3
|
-316.1
|
-378.4
|
-389
|
-391.5
|
-379.1
|
-371.5
|
-315.2
|
Operating Margin
|
-361.57%
|
-155.59%
|
-
|
-2,732.07%
|
-1,459.52%
|
-898.05%
|
-326.64%
|
-159.56%
|
Earnings before Tax (EBT)
1 |
-411.5
|
-327.4
|
-356.5
|
-231.8
|
-352.1
|
-284.3
|
-323.6
|
-255.3
|
Net income
1 |
-411.5
|
-327.4
|
1,605
|
-231.8
|
-352.1
|
-318.2
|
-361
|
-299.9
|
Net margin
|
-348.97%
|
-161.11%
|
-
|
-1,627.82%
|
-1,312.63%
|
-753.65%
|
-317.41%
|
-151.82%
|
EPS
2 |
-6.860
|
-4.740
|
26.55
|
-4.230
|
-6.330
|
-5.479
|
-5.886
|
-4.459
|
Free Cash Flow
1 |
-382.8
|
-305.7
|
-413.1
|
-314.4
|
-297.1
|
-335.7
|
-247.5
|
-234.4
|
FCF margin
|
-324.64%
|
-150.43%
|
-
|
-2,207.58%
|
-1,107.49%
|
-795.22%
|
-217.57%
|
-118.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
0.832
|
5.582
|
3.516
|
4.31
|
5.609
|
6.712
|
7.399
|
7.103
|
8.372
|
9.508
|
11.14
|
12.72
|
38.16
|
EBITDA
1 |
-88.94
|
-
|
-
|
-
|
-
|
-
|
-88.82
|
-91.89
|
-
|
-104.9
|
-100
|
-99
|
-100
|
100
|
-
|
EBIT
1 |
-91.15
|
-104.8
|
-101.1
|
-97.64
|
-91.09
|
-99.17
|
-90.61
|
-93.7
|
-100.9
|
-106.3
|
-99.43
|
-100.5
|
-99.19
|
-79.67
|
-75.98
|
Operating Margin
|
-
|
-
|
-12,156.85%
|
-1,749.19%
|
-2,590.73%
|
-2,300.97%
|
-1,615.49%
|
-1,396.01%
|
-1,363.66%
|
-1,496.23%
|
-1,187.64%
|
-1,057.42%
|
-890.3%
|
-626.34%
|
-199.11%
|
Earnings before Tax (EBT)
1 |
-84.26
|
-98.58
|
-94.77
|
-91.81
|
-81.75
|
36.53
|
-81.02
|
-83.81
|
-91.32
|
-95.94
|
-91.22
|
-92.67
|
-58.48
|
-27.16
|
-67.36
|
Net income
1 |
-88.77
|
-94.63
|
-94.77
|
-91.81
|
-81.75
|
36.53
|
-81.02
|
-83.81
|
-91.32
|
-95.94
|
-94.18
|
-94.73
|
-69.25
|
-50.95
|
-67.36
|
Net margin
|
-
|
-
|
-11,391.11%
|
-1,644.68%
|
-2,325%
|
847.47%
|
-1,444.43%
|
-1,248.6%
|
-1,234.27%
|
-1,350.7%
|
-1,124.89%
|
-996.36%
|
-621.6%
|
-400.58%
|
-176.51%
|
EPS
2 |
-1.560
|
-1.740
|
-1.740
|
-1.680
|
-1.490
|
0.6700
|
-1.470
|
-1.510
|
-1.640
|
-1.720
|
-1.647
|
-1.662
|
-1.244
|
-0.9519
|
-1.170
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/11/21
|
24/02/22
|
05/05/22
|
04/08/22
|
03/11/22
|
23/02/23
|
04/05/23
|
03/08/23
|
02/11/23
|
15/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
36.5
|
-
|
Net Cash position
1 |
80.9
|
311
|
203
|
122
|
30.1
|
68.8
|
-
|
112
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.0893
x
|
-
|
Free Cash Flow
1 |
-383
|
-306
|
-413
|
-314
|
-297
|
-336
|
-247
|
-234
|
ROE (net income / shareholders' equity)
|
-62%
|
-63%
|
190%
|
-19.4%
|
-36.8%
|
-42.5%
|
-43.4%
|
-26.5%
|
ROA (Net income/ Total Assets)
|
-47%
|
-37.5%
|
140%
|
-17.3%
|
-32.4%
|
-17.9%
|
-36.7%
|
-22.4%
|
Assets
1 |
874.6
|
871.8
|
1,145
|
1,338
|
1,088
|
1,778
|
983.2
|
1,340
|
Book Value Per Share
2 |
10.70
|
5.790
|
21.40
|
20.10
|
14.60
|
12.50
|
11.40
|
9.250
|
Cash Flow per Share
2 |
-
|
-
|
-6.740
|
-5.650
|
-5.320
|
-4.770
|
-4.640
|
-
|
Capex
1 |
12.2
|
14.9
|
5.74
|
4.88
|
1
|
5.27
|
6.77
|
12
|
Capex / Sales
|
10.32%
|
7.34%
|
-
|
34.28%
|
3.72%
|
12.47%
|
5.95%
|
6.05%
|
Announcement Date
|
13/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
15/02/24
|
-
|
-
|
-
|
Last Close Price
31.49
USD Average target price
40.67
USD Spread / Average Target +29.14% Consensus |
1st Jan change
|
Capi.
|
---|
| +41.40% | 1.79B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|